These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Persistence of immune responses after heterologous and homologous third COVID-19 vaccine dose schedules in the UK: eight-month analyses of the COV-BOOST trial. Liu X; Munro APS; Wright A; Feng S; Janani L; Aley PK; Babbage G; Baker J; Baxter D; Bawa T; Bula M; Cathie K; Chatterjee K; Dodd K; Enever Y; Fox L; Qureshi E; Goodman AL; Green CA; Haughney J; Hicks A; Jones CE; Kanji N; van der Klaauw AA; Libri V; Llewelyn MJ; Mansfield R; Maallah M; McGregor AC; Minassian AM; Moore P; Mughal M; Mujadidi YF; Belhadef HT; Holliday K; Osanlou O; Osanlou R; Owens DR; Pacurar M; Palfreeman A; Pan D; Rampling T; Regan K; Saich S; Saralaya D; Sharma S; Sheridan R; Stokes M; Thomson EC; Todd S; Twelves C; Read RC; Charlton S; Hallis B; Ramsay M; Andrews N; Lambe T; Nguyen-Van-Tam JS; Cornelius V; Snape MD; Faust SN; J Infect; 2023 Jul; 87(1):18-26. PubMed ID: 37085049 [TBL] [Abstract][Full Text] [Related]
4. Safety and immunogenicity of a modified mRNA-lipid nanoparticle vaccine candidate against COVID-19: Results from a phase 1, dose-escalation study. Essink BJ; Shapiro C; Isidro MGD; Bradley P; Pragalos A; Bloch M; Santiaguel J; Frias MV; Miyakis S; Alves de Mesquita M; Berrè S; Servais C; Waugh N; Hoffmann C; Baba E; Schönborn-Kellenberger O; Wolz OO; Koch SD; Ganyani T; Boutet P; Mann P; Mueller SO; Ramanathan R; Gaudinski MR; Vanhoutte N Hum Vaccin Immunother; 2024 Dec; 20(1):2408863. PubMed ID: 39422261 [TBL] [Abstract][Full Text] [Related]
5. Safety and immunogenicity of an egg-based inactivated Newcastle disease virus vaccine expressing SARS-CoV-2 spike: Interim results of a randomized, placebo-controlled, phase 1/2 trial in Vietnam. Duc Dang A; Dinh Vu T; Hai Vu H; Thanh Ta V; Thi Van Pham A; Thi Ngoc Dang M; Van Le B; Huu Duong T; Van Nguyen D; Lawpoolsri S; Chinwangso P; McLellan JS; Hsieh CL; Garcia-Sastre A; Palese P; Sun W; Martinez JL; Gonzalez-Dominguez I; Slamanig S; Manuel Carreño J; Tcheou J; Krammer F; Raskin A; Minh Vu H; Cong Tran T; Mai Nguyen H; Mercer LD; Raghunandan R; Lal M; White JA; Hjorth R; Innis BL; Scharf R Vaccine; 2022 Jun; 40(26):3621-3632. PubMed ID: 35577631 [TBL] [Abstract][Full Text] [Related]
6. Preserved recognition of Omicron spike following COVID-19 messenger RNA vaccination in pregnancy. Bartsch YC; Atyeo C; Kang J; Cai Y; Chen B; Gray KJ; Edlow AG; Alter G Am J Obstet Gynecol; 2022 Sep; 227(3):493.e1-493.e7. PubMed ID: 35430229 [TBL] [Abstract][Full Text] [Related]
7. Antibody prevalence after three or more COVID-19 vaccine doses in individuals who are immunosuppressed in the UK: a cross-sectional study from MELODY. Pearce FA; Lim SH; Bythell M; Lanyon P; Hogg R; Taylor A; Powter G; Cooke GS; Ward H; Chilcot J; Thomas H; Mumford L; McAdoo SP; Pettigrew GJ; Lightstone L; Willicombe M Lancet Rheumatol; 2023 Aug; 5(8):e461-e473. PubMed ID: 38251578 [TBL] [Abstract][Full Text] [Related]
8. Effectiveness of mRNA boosters after homologous primary series with BNT162b2 or ChAdOx1 against symptomatic infection and severe COVID-19 in Brazil and Scotland: A test-negative design case-control study. Cerqueira-Silva T; Shah SA; Robertson C; Sanchez M; Katikireddi SV; de Araujo Oliveira V; Paixão ES; Rudan I; Junior JB; Penna GO; Pearce N; Werneck GL; Barreto ML; Boaventura VS; Sheikh A; Barral-Netto M PLoS Med; 2023 Jan; 20(1):e1004156. PubMed ID: 36630477 [TBL] [Abstract][Full Text] [Related]
9. Omicron variant Spike-specific antibody binding and Fc activity are preserved in recipients of mRNA or inactivated COVID-19 vaccines. Bartsch YC; Tong X; Kang J; Avendaño MJ; Serrano EF; García-Salum T; Pardo-Roa C; Riquelme A; Cai Y; Renzi I; Stewart-Jones G; Chen B; Medina RA; Alter G Sci Transl Med; 2022 Apr; 14(642):eabn9243. PubMed ID: 35289637 [TBL] [Abstract][Full Text] [Related]
10. Antibody response to SARS-CoV-2 mRNA vaccination in Danish adults exposed to perfluoroalkyl substances (PFASs): The ENFORCE study. Timmermann A; Johansen IS; Tolstrup M; Heilmann C; Budtz-Jørgensen E; Tolstrup JS; Nielsen F; Grandjean P Environ Res; 2024 Dec; 263(Pt 1):120039. PubMed ID: 39326653 [TBL] [Abstract][Full Text] [Related]
11. COVID-19 mRNA vaccines drive differential antibody Fc-functional profiles in pregnant, lactating, and nonpregnant women. Atyeo C; DeRiso EA; Davis C; Bordt EA; De Guzman RM; Shook LL; Yonker LM; Fasano A; Akinwunmi B; Lauffenburger DA; Elovitz MA; Gray KJ; Edlow AG; Alter G Sci Transl Med; 2021 Oct; 13(617):eabi8631. PubMed ID: 34664972 [TBL] [Abstract][Full Text] [Related]
12. Comparison of antibody responses of heterologous and homologous Covid-19 booster vaccination: an observational study. Rizvi NB; Bibi M; Rana MZ; Zaffar S; Farooq H Front Immunol; 2024; 15():1448408. PubMed ID: 39606247 [TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of PfSPZ Vaccine against malaria in healthy adults and women anticipating pregnancy in Mali: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials. Diawara H; Healy SA; Mwakingwe-Omari A; Issiaka D; Diallo A; Traore S; Soumbounou IH; Gaoussou S; Zaidi I; Mahamar A; Attaher O; Fried M; Wylie BJ; Mohan R; Doan V; Doritchamou JYA; Dolo A; Morrison RD; Wang J; Hu Z; Rausch KM; Zeguime A; Murshedkar T; Kc N; Sim BKL; Billingsley PF; Richie TL; Hoffman SL; Dicko A; Duffy PE; Lancet Infect Dis; 2024 Dec; 24(12):1366-1382. PubMed ID: 39153490 [TBL] [Abstract][Full Text] [Related]
14. Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in people living with and without HIV in South Africa: an interim analysis of a randomised, double-blind, placebo-controlled, phase 1B/2A trial. Madhi SA; Koen AL; Izu A; Fairlie L; Cutland CL; Baillie V; Padayachee SD; Dheda K; Barnabas SL; Bhorat QE; Briner C; Aley PK; Bhikha S; Hermanus T; Horne E; Jose A; Kgagudi P; Lambe T; Masenya M; Masilela M; Mkhize N; Moultrie A; Mukendi CK; Moyo-Gwete T; Nana AJ; Nzimande A; Patel F; Rhead S; Taoushanis C; Thombrayil A; van Eck S; Voysey M; Villafana TL; Vekemans J; Gilbert SC; Pollard AJ; Moore PL; Kwatra G; Lancet HIV; 2021 Sep; 8(9):e568-e580. PubMed ID: 34416193 [TBL] [Abstract][Full Text] [Related]
15. Enhanced placental antibody transfer efficiency with longer interval between maternal respiratory syncytial virus vaccination and birth. Jasset OJ; Lopez Zapana PA; Bahadir Z; Shook L; Dennis M; Gilbert E; Liu ZA; Yinger RV; Bald C; Bradford CG; Silfen AH; Klein SL; Pekosz A; Permar S; Konnikova L; Yonker LM; Lauffenburger D; Nelson A; Elovitz MA; Edlow AG Am J Obstet Gynecol; 2024 Nov; ():. PubMed ID: 39515450 [TBL] [Abstract][Full Text] [Related]
16. Humoral responses to wild type and ancient BA.1 SARS-CoV-2 variant after heterologous priming vaccination with ChAdOx1 nCoV-19 and BNT162b2 booster dose. Sanna G; Marongiu A; Firinu D; Piras C; Palmas V; Galdiero M; Atzori L; Caria P; Campagna M; Perra A; Costanzo G; Coghe F; Littera R; Chessa L; Manzin A Clin Exp Med; 2024 Jan; 24(1):12. PubMed ID: 38244064 [TBL] [Abstract][Full Text] [Related]
17. Antibody responses against SARS-CoV-2 variants induced by four different SARS-CoV-2 vaccines in health care workers in the Netherlands: A prospective cohort study. van Gils MJ; Lavell A; van der Straten K; Appelman B; Bontjer I; Poniman M; Burger JA; Oomen M; Bouhuijs JH; van Vught LA; Slim MA; Schinkel M; Wynberg E; van Willigen HDG; Grobben M; Tejjani K; van Rijswijk J; Snitselaar JL; Caniels TG; ; Vlaar APJ; Prins M; de Jong MD; de Bree GJ; Sikkens JJ; Bomers MK; Sanders RW PLoS Med; 2022 May; 19(5):e1003991. PubMed ID: 35580156 [TBL] [Abstract][Full Text] [Related]
18. SARS-CoV-2 BA.4/5 infection triggers more cross-reactive FcγRIIIa signaling and neutralization than BA.1, in the context of hybrid immunity. Richardson SI; Mzindle N; Motlou T; Manamela NP; van der Mescht MA; Lambson BE; Everatt J; Amoako DG; Balla S; von Gottberg A; Wolter N; de Beer Z; de Villiers TR; Bodenstein A; van den Berg G; Abdullah F; Rossouw TM; Boswell MT; Ueckermann V; Bhiman JN; Moore PL J Virol; 2024 Jul; 98(7):e0067824. PubMed ID: 38953380 [TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of the intranasal spray SARS-CoV-2 vaccine dNS1-RBD: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Zhu F; Huang S; Liu X; Chen Q; Zhuang C; Zhao H; Han J; Jaen AM; Do TH; Peter JG; Dorado AG; Tirador LS; Zabat GMA; Villalobos REM; Gueco GP; Botha LLG; Iglesias Pertuz SP; Tan J; Zhu K; Quan J; Lin H; Huang Y; Jia J; Chu X; Chen J; Chen Y; Zhang T; Su Y; Li C; Ye X; Wu T; Zhang J; Xia N; Lancet Respir Med; 2023 Dec; 11(12):1075-1088. PubMed ID: 37979588 [TBL] [Abstract][Full Text] [Related]